Open AccessBrief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial
Author(s) -
Princy Kumar,
Margaret Johnson,
JeanMichel Molina,
Giuliano Rizzardini,
Pedro Cahn,
Markus Bickel,
Hong Wan,
Zhi Jin Xu,
Cristiana Morais,
Peter Sklar,
Wayne Greaves
Publication year - 2021
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002642
Subject(s) - medicine , regimen , lamivudine , adverse effect , viral load , randomized controlled trial , human immunodeficiency virus (hiv) , emtricitabine , gastroenterology , immunology , virus , antiretroviral therapy , hepatitis b virus